MarketFriction

Venmax Drugs & Pharmaceuticals Ltd

BSE 531015 · Pharmaceuticals
₹14.50 -2.09%
BSE close2026-10-01
Market cap₹21.7 Cr.
P/E77.5

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales0.000.000.000.100.170.200.331.211.321.553.942.48
Expenses0.030.010.040.120.470.690.571.171.271.583.922.36
Operating Profit-0.03-0.01-0.04-0.02-0.30-0.49-0.240.040.05-0.030.020.12
OPM %-20.00%-176.47%-245.00%-72.73%3.31%3.79%-1.94%0.51%4.84%
Other Income0.000.050.100.030.000.001.020.000.000.070.090.00
Interest0.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation0.000.000.000.000.000.000.000.000.000.000.000.00
Profit before tax-0.030.040.060.01-0.30-0.490.780.040.050.040.110.12
Tax %0.00%25.00%16.67%0.00%0.00%0.00%0.00%0.00%40.00%25.00%0.00%0.00%
Net Profit-0.030.030.050.01-0.30-0.500.780.040.020.030.110.12
EPS in Rs-0.060.060.100.02-0.57-0.951.490.080.020.040.090.10
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1.930.260.000.150.470.170.000.000.000.818.029.29
Expenses2.070.880.230.380.720.500.120.190.111.877.909.13
Operating Profit-0.14-0.62-0.23-0.23-0.25-0.33-0.12-0.19-0.11-1.060.120.16
OPM %-7.25%-238.46%-153.33%-53.19%-194.12%-130.86%1.50%1.72%
Other Income0.00-0.720.000.000.000.181.980.420.201.050.160.16
Interest0.000.000.010.000.000.000.000.000.000.000.000.00
Depreciation0.000.000.000.010.010.010.010.010.010.010.000.00
Profit before tax-0.14-1.34-0.24-0.24-0.26-0.161.850.220.08-0.020.280.32
Tax %0.00%0.00%0.00%0.00%3.85%0.00%0.00%0.00%25.00%0.00%10.71%
Net Profit-0.14-1.34-0.24-0.24-0.27-0.161.850.230.06-0.010.250.28
EPS in Rs-0.27-2.56-0.46-0.46-0.52-0.313.530.440.11-0.020.220.25
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth15%116%%386%
Compounded Profit Growth14%29%3%1300%
Stock Price CAGR20%%%-32%
Return on Equity%%%3%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5.245.245.245.245.245.245.245.245.245.245.2411.58
Reserves-4.90-5.04-7.11-7.35-7.59-7.86-8.03-6.18-5.95-5.89-0.832.53
Borrowings1.501.721.852.042.242.522.330.350.350.350.050.33
Other Liabilities1.850.680.160.140.440.560.760.800.570.380.711.76
Total Liabilities3.692.600.140.070.330.460.300.210.210.085.1716.20
Fixed Assets0.000.000.000.000.110.100.090.080.070.070.040.04
CWIP0.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.010.010.000.000.000.000.000.000.000.000.000.00
Other Assets3.682.590.140.070.220.360.210.130.140.015.1316.16
Total Assets3.692.600.140.070.330.460.300.210.210.085.1716.20
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-0.10-0.19-1.06-0.26-0.05-0.280.261.910.000.00-2.29-11.00
Cash from Investing Activity0.000.000.010.00-0.110.000.000.000.000.000.000.00
Cash from Financing Activity0.100.221.020.260.160.28-0.19-1.980.000.004.779.74
Net Cash Flow0.000.03-0.030.000.000.000.07-0.070.000.002.48-1.26
Free Cash Flow-0.10-0.19-1.05-0.26-0.17-0.280.261.910.000.00-2.29-11.00
CFO/OP127%136%171%113%22%112%-79%-1,592%0%-18%216%-9,142%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days21.03128.600.000.0031.0685.88428.0965.08
Inventory Days225.440.000.00446.11250.940.0027.7250.14
Days Payable251.511,257.22456.25291.0884.23
Cash Conversion Cycle-5.04128.600.00-811.11-174.2585.88164.7330.99
Working Capital Days-3.005.67-2,723.46-5,986.00-2,112.34-6,333.82874.20587.55
ROCE %-6.01%-7.45%-52.63%-0.96%2.96%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters23.13%23.13%23.13%23.13%23.13%23.13%23.13%23.13%23.13%15.14%13.80%10.46%
DIIs0.15%0.15%0.15%0.15%0.15%0.15%0.15%0.00%0.00%0.00%0.00%0.00%
Public76.71%76.71%76.71%76.71%76.72%76.72%76.71%76.87%76.86%84.86%86.21%89.53%
No. of Shareholders6,2506,2526,2516,2526,2916,6576,7566,7296,7646,8156,8026,865

Fundamentals

Market Cap₹ 21.7 Cr.
Current Price₹ 15.0
Stock P/E77.5
Book Value₹ 13.0
ROCE2.96 %
ROE2.70 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)386%
Compounded Profit Growth (TTM)1300%
Standalone figures.
Valuation
Market capRs 17 Cr
Enterprise valueRs 16 Cr
P/E (TTM)59.98x
Price to book1.19x
Price to sales1.81x
EV / EBITDA49.70x
EV / EBIT49.70x
EV / sales1.71x
Earnings yield1.67%
P/E, 3-year average77.95x
P/B, 3-year average0.71x
P/E, 5-year average41.65x
P/B, 5-year average-0.66x
Profitability
Operating margin (excl. other income)1.50%
Operating margin (incl. other income)3.49%
EBITDA margin3.44%
Pre-tax margin3.44%
Net profit margin3.01%
Net margin, latest quarter4.84%
ROE2.70%
ROCE2.96%
ROA2.34%
ROE, 3-year average-2.22%
ROCE, 3-year average1.00%
ROA, 3-year average14.45%
ROE, 5-year average-26.75%
ROCE, 5-year average1.00%
ROA, 5-year average175.67%
ROIC (approx.)2.16%
Tax rate10.71%
Other income / net worth1.13%
Growth
Sales growth (latest year)890.12%
Sales CAGR, 5 years116.14%
Profit CAGR, 3 years2.82%
Sales growth QoQ-37.06%
Profit growth QoQ9.09%
Sales growth YoY (latest quarter)104.96%
Profit growth YoY (latest quarter)200.00%
Per share
EPS (TTM)Rs 0.24
EPS (latest year)Rs 0.22
EPS (latest quarter)Rs 0.10
EPS, 3-year averageRs 0.10
EPS, 5-year averageRs 0.86
Book value per shareRs 12.18
Sales per shareRs 8.02
Cash flow per shareRs -9.50
Free cash flow per shareRs -9.50
Efficiency
Asset turnover0.50x
Fixed asset turnover200.50x
Inventory turnover7.29x
Inventory days50 days
Debtor days65 days
Debtors turnover5.61x
Creditor days84 days
Cash conversion cycle31 days
Working capital days588 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 1 Cr
Net debtRs -1 Cr
Debt to equity0.02x
Net debt / EBITDA-2.78x
Owners' fund to total sources87.10%
Debt to assets2.04%
Cash flow
Cash from Operating Activity (latest year)Rs -11 Cr
Cash from Financing Activity (latest year)Rs 10 Cr
Net Cash Flow (latest year)Rs -1 Cr
Free cash flow (latest year)Rs -11 Cr
FCFE (approx.: FCF + change in debt)Rs -11 Cr
Cash from ops / profit, 5 years-4.78x
Statement figures
Net sales (TTM)Rs 9 Cr
Net sales (latest year)Rs 8 Cr
Sales (latest quarter)Rs 2 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Net profit (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 7 Cr
Total expenditure (latest year)Rs 8 Cr
Total income (latest year)Rs 8 Cr
Share capitalRs 12 Cr
ReservesRs 3 Cr
Shareholders' fundsRs 14 Cr
Total assetsRs 16 Cr
Net blockRs 0 Cr
ReceivablesRs 1 Cr
InventoryRs 1 Cr
Other liabilitiesRs 2 Cr
Shares outstanding (crore)1.16
Ownership
Promoter holding10.46% (-12.67 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Period531015Nifty 50Difference
1 week-8.8%-2.8% -6.0 pts
1 month-8.5%-6.8% -1.7 pts
3 months-17.3%-7.6% -9.7 pts
3 years+246.9%+14.2% +232.7 pts
5 years+246.9%+27.9% +219.0 pts

Red flags

F-score 4 of 8
explainHigh accruals Profit exceeded operating cash by 69% of total assets in 2026
explainShare dilution Share count up 123% in a year, 123% in three
lookInventory outrunning sales Inventory grew 1567% vs sales +890% in 2026
lookProfit leans on other income Other income was 57% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹2 Cr +105.0% vs Jun 2025. Net profit ₹0 Cr +200.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Venmax Drugs & Pharmaceuticals Ltd?

Venmax Drugs & Pharmaceuticals Ltd (531015) has a market capitalisation of Rs 21.7 Cr. at the 2026-10-01 close.

What is the P/E ratio of Venmax Drugs & Pharmaceuticals Ltd?

Venmax Drugs & Pharmaceuticals Ltd trades at a P/E of 77.5 on trailing twelve-month profit, at the 2026-10-01 close.

What were Venmax Drugs & Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Venmax Drugs & Pharmaceuticals Ltd sales was Rs 2 Cr (+105.0% vs Jun 2025) and net profit was Rs 0 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03